Advancements in Targeted Therapies for Genitourinary Cancers

Genitourinary (GU) cancers encompass prostate, bladder, kidney, and testicular cancers, significantly impacting global health. While traditional treatments like surgery, radiation, and chemotherapy are foundational, the landscape of GU cancer treatment is being revolutionized by targeted therapies. Notable advancements include the use of FGFR inhibitors in bladder cancer due to aberrant FGFR3 signaling, PARP inhibitors for BRCA-mutated prostate cancers, and belzutifan targeting the HIF-2α pathway in kidney cancer. These innovations underscore a shift towards precision medicine, propelled by an evolving understanding of molecular pathways driving these cancers.

This Research Topic aims to explore innovative therapeutics and novel mechanisms in GU cancers. The goal of this collection is to enhance the understanding of molecular signaling pathways and address the challenges of drug resistance in GU cancers. Through this endeavor, the Research Topic seeks to establish a comprehensive resource for the latest developments in GU cancer biology, promoting translational research that bridges experimental findings with clinical applications. 

We are particularly interested in original research articles discussing novel approaches, mechanisms, or therapies in GU cancer. Review articles are not preferred for this collection.

To gather further insights into therapeutic advancements in GU cancers, we invite submissions that span a broad spectrum of research. We are especially interested in:

- Novel targeted therapies
- Mechanisms of drug resistance
- Immunotherapy strategies
- Multi-omic analytical approaches
- Mechanistic studies of key signaling pathways
- Translational research that integrates laboratory findings with patient care

These themes are intended to foster a deeper understanding of GU cancer progression and to highlight emergent strategies that could notably improve patient outcomes.

Article types and fees

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Case Report
• Clinical Trial
• Editorial
• FAIR² Data
• FAIR² DATA Direct Submission
• General Commentary
• Hypothesis and Theory
• Methods
• ... View all formats

Articles that are accepted for publication by our external editors following rigorous peer review incur a publishing fee charged to Authors, institutions, or funders.

Article types

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Case Report
• Clinical Trial
• Editorial
• FAIR² Data
• FAIR² DATA Direct Submission
• General Commentary
• Hypothesis and Theory
• Methods
• Mini Review
• Opinion
• Original Research
• Perspective
• Policy and Practice Reviews
• Review
• Study Protocol
• Systematic Review
• Technology and Code

Keywords: Cancer, genomics, genetics, cancer immunology, AI/ML

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.